This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Close Message
NextPharmaJob.com for pharmaceutical industry jobs
FirstMedcommsJob
NextPharmaJob.com is dedicated to putting job seekers looking for pharmaceutical industry jobs in touch with recruiters and employers.
Browse Jobs Search Jobs
Location
Switzerland (227)
France (205)
Germany (147)
Belgium (101)
Italy (89)
Denmark (10)
Austria (8)
Spain (8)
Australia (5)
China (2)
Russia (2)
Israel (1)
Japan (1)
Turkey (1)

To receive a FREE weekly email alert of all the latest pharmaceutical industry jobs added to our database enter your email address below.

Submit | Tell me more...

Sister sites:
Our sister site Our sister site
Partner sites:

At Burntsky Limited we work with a number of third parties in order to maximise the reach of the jobs posted with us including but not limited to:

JooblePartner Jooble
UK Jobs
Science Jobs

Industry News
11 December 2018 08:05Cerecin Sponsors and Presents at Alzheimer's Disease Therapeutics: Alternatives to Amyloid Symposium
SINGAPORE, Dec. 11, 2018 /PRNewswire/ -- Brain health-focused pharmaceutical company Cerecin, today announced that it is a sponsor for the Alzheimer's Disease Therapeutics: Alternatives to Amyloid Symposium to be held in New York, New York, USA. Dr

11 December 2018 07:10World-first Approval For Multiple Myeloma Drug APLIDIN(R)
Australia's Therapeutic Goods Administration approves APLIDIN (plitidepsin) for relapsed/refractory multiple myeloma patients APLIDIN will continue to be made available to eligible patients via a Compassionate Access Program, pending reimbursement

11 December 2018 06:00Dr Annalisa Jenkins and Lord Michael Grade Appointed as Advisors to AKL Research & Development
STEVENAGE, England, December 11, 2018 /PRNewswire/ -- Appointments bolster team dedicated to bringing osteoarthritis drug to market AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, today

10 December 2018 02:00Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
TOKYO, Dec. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced that XOSPATA® (generic name: gilteritinib) is now available for prescription in the United States for the tre

10 December 2018 22:40Statement from Jeff Shuren, M.D., J.D., Director of the Center for Devices and Radiological Health, on updated safety communication about rates of duodenoscope contamination from preliminary postmarket data
SILVER SPRING, Md., Dec. 10, 2018 /PRNewswire/ -- Advancing medical device safety remains a top priority of the U.S. Food and Drug Administration. This means we are committed to communicating when new, relevant information becomes available about d

10 December 2018 21:41Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials
THOUSAND OAKS, Calif. and SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have te

10 December 2018 21:15Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors
SAN DIEGO, Dec. 10, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Maya Martinez-Davis to the Company's Board of Directors, effective immediately. Ms. Ma

10 December 2018 21:10Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million
DUBLIN, Dec. 10, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its Board of Directors has authorized a $400 million increase in the company's share repurchase program, which the company intends to use over time b

10 December 2018 20:46FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs
SILVER SPRING, Md., Dec. 10, 2018 /PRNewswire/ -- Today, the U.S. Food and Drug Administration cleared a mobile medical application (app) to help increase retention (the amount of time a patient participates) in an outpatient treatment program for

10 December 2018 20:04Dominion Diagnostics Establishes New Scholarship to Enhance Access to Vermont Recovery Residences
WILLISTON, Vt., Dec. 10, 2018 /PRNewswire/ -- A new scholarship advancing addiction recovery in the state of Vermont has been established to support the Vermont Foundation of Recovery (VFOR) by Dominion Diagnostics, a leading national medical labor

10 December 2018 16:05Statement from FDA Commissioner Scott Gottlieb, M.D. and Deputy Commissioner Anna Abram on new efforts to assure the quality of compounded drugs
SILVER SPRING, Md., Dec. 10, 2018 /PRNewswire/ -- As we continue to implement our 2018 Compounding Priorities Plan, our mission is to preserve patient access to compounded drugs to meet patients' individual medical needs while also protecting patie

10 December 2018 15:35Covanta Recognized for Environmental Achievement and Sustainability Leadership with 2018 SEAL Award
MORRISTOWN, N.J., Dec. 10, 2018 /PRNewswire/ -- Covanta, (NYSE: CVA) a world leader in sustainable waste and energy solutions, has been recognized with the 2018 Sustainability, Environmental Achievement & Leadership (SEAL) for its leadership in

10 December 2018 15:30Immix Observes Clinical Benefit at Dose-Level 2 in Phase 1b Clinical Trial in Refractory Cancer
LOS ANGELES, Dec. 10, 2018 /PRNewswire/ -- Immix Biopharma, Inc announced today positive interim results from its ongoing phase 1b/2a study testing IMX-110 in advanced solid tumors. Immix observed Stable Disease at cohort (dose-level) 2 in a middl

10 December 2018 15:13ISM® Reports Economic Growth To Continue In 2019
Manufacturing Growth Expected in 2019 Revenue to Increase 5.7% Capital Expenditures to Increase 6% Capacity Utilization Currently at 85.2% Non-Manufacturing Growth Projected in 2019 Revenue to Increase 3.7% Capital Expenditures to Increase 3.4% Cap

10 December 2018 14:04Clinical Trial Published in the Journal of Shoulder and Elbow Surgery Concludes That CollPlant's Vergenix(TM) STR Effectively Demonstrates Significant Clinical Improvements in Tennis Elbow
NESS ZIONA, Israel, December 10, 2018 /PRNewswire/ -- 59%  improvement in a key measure in patients with chronic tennis elbow at 6 months after treatment  Vergenix™STR is currently sold in Europe; CollPlant plans to pursue FDA regulatory approva

10 December 2018 14:00Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Confirms Efficacy, Safety, and Tolerability Through Five Years
SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Medicines360, a global nonprofit women's health pharmaceutical company, announced newly published data finding that LILETTA is highly efficacious in preventing pregnancy over five years of use. In addit

10 December 2018 13:52Perrigo Announces the Launch of an AB Rated Generic Version of Topicort® Topical Spray 0.25%
DUBLIN, Dec. 10, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Topicort® (desoximetasone)Topical Spray 0.25%. Topicort® Topical Spray is indicated for the treatment of pl

10 December 2018 13:35Citius Pharmaceuticals Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation CRANFORD, N.J., Dec. 10, 2018 /PRNewswire/ -- Citius Pharmaceuticals (NASDAQ: CTXR), based in New Jersey,

10 December 2018 13:00Hypoparathyroidism Treatment Market Will Reach at a CAGR of 8% From 2018 to 2026
VALLEY COTTAGE, New York, December 10, 2018 /PRNewswire/ -- The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately

10 December 2018 13:00Successful First in Human for ZygoFix's Spinal Facet Joint Fixation System
MISGAV, Israel, Dec. 10, 2018 /PRNewswire/ -- ZygoFix Ltd. ("ZygoFix"), a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTCQX: TRNLY), announced the successful start of a first In human clinical study for its zLOCK s
News last updated 11/12/2018 08:32:49
line graphic

Compatible with:

JobMate   Broadbean   Idibu

Site optimised for Internet Explorer 8+ / Firefox 3+
View a complete Jobs Listing




Credit cards image